Compare SFIX & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SFIX | RLMD |
|---|---|---|
| Founded | 2011 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 412.3M | 461.9M |
| IPO Year | 2017 | 2012 |
| Metric | SFIX | RLMD |
|---|---|---|
| Price | $2.21 | $3.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | $4.50 | ★ $12.40 |
| AVG Volume (30 Days) | ★ 2.4M | 1.1M |
| Earning Date | 06-09-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 59.09 | 45.28 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,226,505,000.00 | $13,070.00 |
| Revenue This Year | $8.04 | N/A |
| Revenue Next Year | $3.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 25.52 | ★ 154.83 |
| 52 Week Low | $2.10 | $1.78 |
| 52 Week High | $5.75 | $8.00 |
| Indicator | SFIX | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 24.48 | 29.92 |
| Support Level | N/A | $3.59 |
| Resistance Level | $3.58 | $4.51 |
| Average True Range (ATR) | 0.13 | 0.22 |
| MACD | -0.02 | -0.02 |
| Stochastic Oscillator | 5.85 | 5.05 |
Stitch Fix Inc offers personal style services for men and women. The company engages in delivering one-to-one personalization to clients through the combination of data science and human judgment. It provides a shipment service called A FIX where the stylist's hand selects items from several merchandise with analysis of client and merchandise data to provide a personalized shipment of apparel, shoes, and accessories suited to the client's needs. The company offers products across categories, brands, product types, and price points including Women's, Petite, Maternity, Men's, and Plus. It also offers various product types, including denim, dresses, blouses, skirts, shoes, jewelry, and handbags and sells merchandise across various ranges of price points.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.